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ABSTRACT
Multiple intracellular signaling pathways stimulate quiescent
smooth muscle cells (SMCs) to exit from G0 and re-enter the
cell cycle. Thus, a combination of two drugs with different
mechanisms of action may represent a suitable approach to
control SMC proliferation, a prominent feature of in-stent reste-
nosis. In the present study, we investigated the effect of everoli-
mus, a mammalian target of rapamycin inhibitor, in combination
with fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A re-
ductase inhibitor, on proliferation of rat SMCs. The antiprolif-
erative action of everolimus was amplified by 2.5-fold by the
addition of subliminal concentrations of fluvastatin (5  107
M), lowering the IC50 value from 2.5  10
9 to 1.0  109 M.
The increased antiproliferative effect of everolimus by fluva-
statin was prevented in the presence of mevalonate, farnesol,
or geranylgeraniol, suggesting the involvement of prenylated
proteins. Cell cycle analysis and [3H]thymidine incorporation
assay demonstrated that the two drugs synergistically inter-
fered with the progression of G1 phase. In particular, the drug
combination significantly up-regulated p27Kip1 levels by 47.0%,
suppressed cyclin E by 43.0%, and it reduced retinoblastoma
(Rb) hyperphosphorylation by 79.0%, compared with everoli-
mus alone. Retroviral overexpression of cyclin E conferred a
significant resistance of rat SMCs to the antiproliferative action
of the drug combination, measured by cell counting, [3H]thy-
midine incorporation, and cell cycle analysis, with higher levels
of hyperphosphorylated form of Rb. Taken together, these re-
sults demonstrated that everolimus acts synergistically with
fluvastatin to inhibit SMC proliferation by altering the expres-
sion of cyclin E and p27kip1, which affects Rb phosphorylation
and leads to G1 phase arrest.
Smooth muscle cell (SMC) proliferation in the arterial wall
is the major determinant of restenosis after balloon angio-
plasty and stent coronary implantation (Ross, 1999; Hans-
son, 2005). The introduction of drug-eluting stent has signif-
icantly improved the restenosis process and the patient
outcome after revascularization; but recently, the safety and
the efficacy of this approach have been reevaluated (Boden et
al., 2007; Stone et al., 2007). Thus, single and/or combined
oral therapy has been proposed as promising approach to
achieve a better clinical outcome after percutaneous coronary
intervention (Mody et al., 2001; Boden et al., 2007). In par-
ticular, a combination of two different pharmacological inhib-
itors capable of antagonizing different intracellular signaling
pathways involved in cell cycle reentry may lead to better
control of SMC proliferation.
The 40-O-(2-hydroxyethyl)-derivative of rapamycin, everoli-
mus, is a proliferation signal inhibitor that affects growth fac-
tor-induced proliferation of hematopoietic and nonhematopoi-
etic cells via cell cycle arrest at the late G1 phase (Price et al.,
1992; Brown et al., 1995; Decker et al., 2003; Hafizi et al.,
2004). The antiproliferative action of everolimus is elicited
through binding to the mammalian target of rapamycin com-
plex (mTORC) 1 composed of mTOR, a common regulatory
subunit called LST8, and the raptor subunit that specifies
the downstream substrates (Schuler et al., 1997; Sarbassov
et al., 2004; Shaw and Cantley, 2006). The binding of everoli-
mus to mTORC1 complex strongly inhibits its catalytic ac-
tivity and the activation of two well characterized mTORC1
complex substrates that control translation and cell growth,
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An erratum has been published:
the p70S6 protein kinase (p70S6) and the eukaryotic trans-
lation initiation factor 4E-binding protein 1 (4E-BP1) family
of proteins (Brown et al., 1995; Brunn et al., 1997). More
recently, everolimus has been shown to directly interfere
with the assembly of the rapamycin-insensitive rictor/mTOR
protein complex, mTORC2, and to block AKT signaling (Zeng
et al., 2007). Thus, the inhibition of both mTORC1 and
mTORC2 is considered the pivotal molecular mechanism for
the antiproliferative effect of everolimus.
The inhibition of cell proliferation is thought to be the basic
molecular mechanism for the multiple actions of everolimus,
such as immunosuppression, prevention of renal and heart
transplant rejection, and retardation of cardiac allograft vas-
culopathy (Schuler et al., 1997; Nashan, 2002). In an exper-
imental model of in-stent restenosis, oral administration of
everolimus inhibited SMC proliferation at similar degree to
that seen with rapamycin-eluting stents, suggesting a poten-
tial oral use of this drug for restenosis (Farb et al., 2002).
This feature has made rapamycin and everolimus an attrac-
tive pharmacological tool for the development of drug-eluting
stents. Indeed, everolimus-eluting stents as rapamycin-elut-
ing stents, have been reported to inhibit in-stent neointimal
growth in patients with coronary artery disease (Grube et al.,
2004).
A second class of drugs that strongly affects cell prolifera-
tion is represented by the HMG-CoA reductase inhibitors,
also called statins. We have previously shown that fluva-
statin interferes with SMC proliferation in vitro at therapeu-
tic concentrations (0.1–1  106 M), and more importantly,
sera from patients treated with fluvastatin can significantly
reduce SMC proliferation in an ex vivo assay (Corsini et al.,
1996). The ability of statins to inhibit SMC proliferation
seems to be independent from their cholesterol-reducing
properties, and more likely to be related to the depletion of
intracellular nonsteroidal isoprenoid compounds, such as far-
nesol (FOH) and geranylgeraniol (GGOH), which inhibits
intracellular protein prenylation process (Corsini et al., 1993;
Raiteri et al., 1997; Bellosta et al., 2000). Several prenylated
proteins belonging to different intracellular signaling path-
ways have been documented to be indispensable for cell pro-
liferation, including the small GTP-binding protein Ras, and
Ras-like proteins, such as Rho, Rac, and Rap (Corsini et al.,
1999; Brown et al., 2006).
Interestingly, the combination fluvastatin everolimus has
been shown previously to have a beneficial effect on graft
vascular disease in a rat model of chronic heart rejection,
measured as arterial intimal thickness, suggesting a poten-
tial positive effect between the two drugs on SMC prolifera-
tion. The basic molecular mechanisms, however, have not
been elucidated (Gregory et al., 2001).
On this basis, in the present study we explored the poten-
tial synergistic inhibitory effect of the combination everoli-
mus fluvastatin on SMC proliferation and the underling mo-
lecular mechanisms.
Materials and Methods
Reagents and Antibodies. DMEM, trypsin ethylenediaminetet-
raacetate, penicillin (10,000 Uml1), streptomycin (10 mgml1), 1 M
Tricine buffer, pH 7.4, nonessential amino acid solution (100), and
fetal calf serum (FCS) were purchased from Invitrogen (Carlsbad,
CA). Disposable culture flasks and Petri dishes were from Corning
Life Sciences (Acton, MA), and filters were from Millipore Corpora-
tion (Billerica, MA). [6-3H]Thymidine, sodium salt (2 Ci/mmol) was
from GE Healthcare (Milan, Italy), and molecular weight protein
standards were from Bio-Rad Laboratories (Hercules, CA). Isoton II
was purchased from Instrumentation Laboratories (Milan, Italy).
SDS, TEMED, ammonium persulfate, glycine, and acrylamide solu-
tion (30% T, 2.6% C) were obtained from Bio-Rad Laboratories.
Cytox-Dye was purchased from Invitrogen. Fluvastatin (Corsini et
al., 1995) and everolimus (SDZ RAD) (Schuler et al., 1997) were
provided by Novartis-Pharma AG (Basel, Switzerland). FOH,
GGOH, and mevalonate (MVA) were from Sigma (Milan, Italy). For
Western blot analysis, the following antibodies were used: anti-cyclin
D1, anti-cyclin E, anti-cdk2, anti-p70S6 kinase, and anti-phospho-
p70S6 kinase Thr 412 (Millipore, Vimodrone, Italy); anti-p27Kip1
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA); anti-Rb protein
(Millipore); anti 4E-BP1 (Cell Signaling Technology Inc., Danvers,
MA); anti-p21Cip1 (Abcam plc, Cambridge, UK); and anti-mouse and
anti-rabbit peroxidase-conjugated secondary antibody (Jackson Im-
munoResearch Laboratories Inc., West Grove, PA).
Cell Proliferation and DNA Synthesis. SMCs were cultured
from the intimal-medial layers of aorta of male Sprague-Dawley rats
as described previously (Corsini et al., 1995). Cells were seeded at a
density of 1  105 SMC/35-mm Petri dish, and then they were
incubated with DMEM supplemented with 10% FCS. Twenty-four
hours later, the medium was changed to medium containing 0.4%
FCS to stop cell growth, and the cultures were incubated for 72 h. At
this time (time 0), the medium was replaced with medium containing
10% FCS in the presence or absence of known concentrations of the
drugs, and the incubation was continued for further 72 h at 37°C.
Cell proliferationwas evaluated by cell countingwith a Coulter Counter
model ZM (Beckman Coulter, Fullerton, CA) after trypsinization of the
monolayers. At time 0, just before the addition of the substances to be
tested, three Petri dishes were used for cell counting. The total cell
number determined at time 0 was subtracted from cell number found in
each triplicate after 72 h of cell growth.
For DNA synthesis, synchronization of SMCs to the G0/G1 phase of
the cell cycle was accomplished by incubating logarithmically grow-
ing cultures (3  105 myocytes/Petri dish) for 5 days in a medium
containing 0.4% FCS. Quiescent cells were then incubated for 16 h in
fresh medium containing 10% FCS in the presence or absence of
drugs. DNA synthesis was estimated by nuclear incorporation of
[3H]thymidine (Ferri et al., 2003).
HMG-CoA Reductase Assay. The experimental conditions were
the same than those used for cell proliferation assay. HMG-CoA
reductase activity was determined by measuring the rate of conver-
sion of radioactive HMG-CoA into MVA in detergent-solubilized cell-
free extract (Corsini et al., 1995). Aliquots of the cell-free extracts
(30–40 g) were assayed in a buffer containing 0.25 M K2HPO4, pH
7.4, 100 mM glucose 6-phosphate, 15 mM NADP, 50 mM dithiothre-
itol, and 110 M HMG-CoA (90,000 dpm/sample [14C]HMG-CoA) in
a total volume of 200 l. Microsomes were preincubated in the
reaction buffer at 37°C for 10 min before the addition of HMG-CoA,
and then they were incubated for 120 min at 37°C with moderate
shaking. The reaction was stopped by the addition of 20 l of 5 M
HCl, and 90,000 dpm [3H]mevalonolactone standard was added to
measure recovery. The reaction solution was then incubated at 37°C
for 30 min to allow lactonization of the mevalonate. The mixture was
extracted twice with 10 ml (20 ml total) of diethyl ether. The top
phase was transferred to a 50-ml conical tube, and the combined
upper phases were dried; the residue was resuspended in acetone,
spotted on a thin layer chromatography plate, and chromatographed
in acetone/benzene (1:1). The activity of HMG-CoA reductase was
expressed as cpm incorporated in mevalonate per microgram of de-
tergent-solubilized protein.
Cell Cycle Analysis. The experimental conditions used were the
same as those used for DNA synthesis assay. Flow cytometry was
used to analyze cell cycle distribution. Cells were trypsinized and
centrifuged for 5 min at 1000 rpm. Pellets were resuspended in 0.5
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ml of permeabilizing buffer of Cytox Dye (0.5 M in 100 mM Tris, pH
7.4, 150 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, and 0.1% Nonidet
P-40). Samples were placed in the dark for 30 min, and the fluores-
cence of individual nuclei was measured. Nuclear Cytox Dye fluores-
cence signal was recorded on the FL2 channel of a FACScan flow
cytometer (BD Biosciences, San Jose, CA) and analyzed with ModFit
LT software (Verity Software House, Topsham, ME). The number of
cells in G0/G1, S, and G2/M phases was expressed as percentages of
total events (10,000 cells) (Ferri et al., 2003).
Western Blot Analysis. Cells were washed twice with phos-
phate-buffered saline and lysed by incubation with a solution of 50
mM Tris, pH 7.5, 150 mM NaCl, and 0.5% Nonidet P-40, containing
protease and phosphatase inhibitor cocktails (Sigma) for 30 min on
ice. Cell lysates were cleared by centrifugation at 14,000g for 10 min,
and protein concentrations were determined using the bicinchoninic
acid protein assay (Pierce Chemical, Rockford, IL). Lysates were
separated by SDS-polyacrylamide gel electrophoresis under reducing
conditions, transferred to Immobilon polyvinylidene difluoride (Mil-
lipore Corporation), and subsequently immunoblotted with primary
antibody following appropriate secondary antibody, before visualiza-
tion by enhanced chemiluminescence (GE Healthcare). Quantitative
densitometric analyses were performed using GelDoc acquisition
system and Quantity One software (Bio-Rad Laboratories).
Generation of Cyclin E Expression Construct and Retrovi-
ral Infection. Full-length rat cyclin E (accession no. D14015) was
generated by polymerase chain reaction using the following primers:
5-ATGAAAGAAGAAGGTGGTTCCG-3 and 5-TCATTCTGTCTC-
CTGCTCACTGC-3. The sequence of the polymerase chain reaction-
generated construct was confirmed by sequencing. Retroviral expres-
sion plasmid was then constructed using the pBM-IRES-PURO
(Garton et al., 2002) expressing the puromycin resistance gene as a
selectable second cistron gene, generated from the original pBM-
IRES-EGFP, generously provided by Garry P. Nolan (Stanford Uni-
versity, Stanford, CA). Retroviral infections of human SMC were
performed as described previously (Garton et al., 2002).
Analysis of Drug Synergism. According to the method of Kern
et al. (1988), the expected value of cell number (CNexp, defined as the
product of the percentage versus control of cell number observed
after incubation with drug A alone and the percentage of cell number
observed for drug B alone divided by 100) and the actual cell number
observed (CNobs) for the combination of A and B were used to con-
struct a synergistic ratio as follows: R  CNexp/CNobs. Synergy was
defined as any value of R greater than unity. An R value of 1.0
(additive effect) or less indicated an absence of synergy (Kern et al.,
1988).
Statistical Analysis. Experimental data are expressed as
mean  S.D. The effects of the tested drugs versus control on the
different parameters were analyzed by two-tailed Student’s t test for
unpaired data. The concentration of everolimus required to inhibit
50% of cell proliferation (IC50) was calculated by nonlinear regres-
sion curve (SigmaPlot software; Systat Software, Inc., Point Rich-
mond, CA).
Results
Fluvastatin Synergistically Improves the Inhibitory
Effect of Everolimus on Arterial SMC Proliferation.
The antiproliferative effect of everolimus was studied on rat
aortic SMCs at concentrations ranging from 5  1010 to 5 
107 M. As shown in Fig. 1A, everolimus decreased SMC
proliferation in a concentration-dependent manner. The con-
centration of everolimus required to inhibit cell proliferation
by 50% (IC50) was 2.5  10
9 M. Although everolimus very
potently reduced cell proliferation, it did not allow a complete
inhibition with 54.9  12.9% inhibitory effect at 5  107 M
(Fig. 1A). A plateau of about 55% inhibition was reached at
concentrations of 5  109 M and above (Fig. 1A).
The inhibitory effect of everolimus on SMC proliferation
was then evaluated in combination with subliminal fluva-
statin concentration (5 107 M). Fluvastatin alone resulted
in a nonsignificant 9.18  8.4% inhibitory effect on rat SMC
proliferation (Fig. 1B). The combination with fluvastatin led
to a potent inhibitory effect of everolimus on cell prolifera-
tion, with an IC50 value equal to 1.0  10
9 M, 2.5-fold lower
than that observed with everolimus alone. The combination
of fluvastatin with everolimus increased the extent of inhi-
bition of cell proliferation from 54.9  12.9% to a maximum
Fig. 1. Effect of everolimus alone or in
combination with fluvastatin on rat
SMC proliferation. A, cells were seeded
at a density of 1  105 per 35-mm dish
and incubated with DMEM supple-
mented with 10% FCS; 24 h later, the
medium was changed with medium
containing 0.4% FCS to stop cell
growth, and the cultures were incu-
bated for 72 h. At this time, themedium
was replaced with medium containing
10% FCS, in the presence or absence of
indicated concentrations of drugs. After
72 h, at 37°C, cell number was evalu-
ated by cell counting after trypsiniza-
tion of the monolayers. Each bar repre-
sents the mean  S.D. of six different
experiments. B, experimental condi-
tions are the same as described in A.
Each bar represents themean S.D. of
three different experiments. , p 0.05
and , p  0.001, fluvastatin versus
control (Student’s t test). C, synergistic
effect of the combination everolimus
with fluvastatin is demonstrated by the
R value greater than unity. The syner-
gistic ratio represents the ratio of ex-
pected inhibitory effect on cell prolifer-
ation and the observed inhibition (Kern
et al., 1988).
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inhibitory effect of 72.4  8.3% at 5  107 M everolimus
concentration (Fig. 1A; Table 1).
To determine whether the antiproliferative action of fluva-
statin in combination with everolimus was additive or syn-
ergistic, data were analyzed according to Kern et al. (1988).
The combination of the two drugs produced an additive effect
until 5  109 M and a synergistic effect with higher con-
centrations, with R values of 1.35 and 1.47 at 108 and 5 
107 M, respectively (Fig. 1C).
In a first attempt to determine the molecular mechanism
responsible for this synergistic action, we evaluated the effect
of everolimus on the inhibitory activity of fluvastatin on its
intracellular target (i.e., HMG-CoA reductase). As shown in
Fig. 2A, 5  107 M fluvastatin up-regulated the HMG-CoA
reductase by 52.5-fold, indicating a significant inhibition of
the enzyme in SMCs (Corsini et al., 1995). A similar induc-
tion of HMG-CoA reductase was observed when fluvastatin
was combined with 108 M everolimus (57.4-fold), indicating
that the addition of everolimus did not alter the pharmaco-
logical action of fluvastatin.
The primary targets of mTORC1, inhibited by everolimus,
are p70S6 kinase and 4E-BP1 (Fingar et al., 2004). The
activation state of p70S6 kinase is closely related to the
phosphorylation of threonine 412 residue, a modification that
is often used as an in vivo readout of mTOR activity (Pearson
et al., 1995). As shown in Fig. 2C, both everolimus alone
(108 M) and in combination with fluvastatin (5  107 M)
completely suppressed the threonine 412 phosphorylation of
p70S6 kinase after 3 days of exposure. Moreover, everolimus
alone and in combination with fluvastatin inhibited, at the
same extent, the accumulation of the phosphorylated form of
4E-BP1 (Fig. 2C).
These results demonstrated that the combination of the
two drugs did not significantly alter the inhibitory action of
fluvastatin and everolimus on HMG-CoA reductase and
mTOR, respectively.
Because the antiproliferative action of fluvastatin is de-
pendent by the inhibition of protein prenylation through a
reduced intracellular availability of FOH and GGOH (Corsini
et al., 1993; Laufs et al., 1999), we investigated the prevent-
ing effect of MVA, the product of the HMG-CoA reductase,
and FOH and GGOH, the substrates of protein prenyl trans-
ferases (Winter-Vann and Casey, 2005), on the antiprolifera-
tive effect of this drug combination. As shown in Fig. 2C, the
coincubation with MVA, FOH, or GGOH abolished the syn-
ergistic antiproliferative effect of the combination everolimus
fluvastatin. These data suggest that fluvastatin enhanced
the inhibitory effect of everolimus on cell proliferation by
affecting the synthesis of the MVA-derived isoprenoid, FOH
and GGOH, substrates of protein prenyl transferases, and
potentially by interfering with protein prenylation.
The Synergistic Effect of Combination Everolimus
Fluvastatin Is Elicited in G1 Phase. Everolimus has been
reported to induce a cell cycle arrest at the G1 phase by
blocking mTOR activity (Schuler et al., 1997; Azzola et al.,
2004), but the effect of the association with fluvastatin has
not been studied. We therefore investigated the effect of
everolimus alone and in combination with fluvastatin on cell
cycle progression using two different approaches: [3H]thymi-
dine incorporation assay and flow cytometry analysis of the
cell cycle. As shown in Fig. 3, everolimus inhibited, in a
concentration dependent manner, the DNA synthesis in-
duced by 10% FCS, with an IC50 value of 6.47  10
9 M. The
combination of everolimus with 2  106 M fluvastatin, a
concentration that did not significantly inhibit [3H]thymi-
dine incorporation, increased the potency of everolimus to
block DNA synthesis, leading to an IC50 value of 1.9  10
10
M (Fig. 3A; Table 1).
We next studied the effect of everolimus in association with
fluvastatin, on the progression of the cell cycle from G1 to S
phase by flow cytometry analysis. Incubation of SMCs with
0.4% FCS led to accumulation of cells at G0/G1 phase (94.8 
2.1%) with only a small percentage at S phase (2.1  0.3%).
After incubation with 10% FCS, we observed a significant
increase in the proportion of SMCs in S phase (22.2  3.3%),
which was decreased to 5.1  0.8% by 107 M everolimus
(Fig. 4). It is noteworthy that we observed no significant
increase in the percentage of cells at sub-G0/G1 phase, dem-
onstrating a specific antiproliferative activity of everolimus
without any induction of apoptosis (Fig. 4). Although everoli-
mus almost completely inhibited the progression from G1
phase to S phase, the combination with 2  106 M fluva-
statin significantly reduced the percentage of cells at S phase
to 3.7 0.3% (Fig. 4; P 0,05). Taken together, these results
indicated that the synergistic antiproliferative action of
everolimus in combination with fluvastatin may be elicited in
G1 phase of the cell cycle.
Fluvastatin Significantly Improves the Effect of
Everolimus on Cyclin E Expression and Rb Phosphor-
ylation. To better define the antiproliferative action of the
combination fluvastatin everolimus in G1 phase, we carried
out a series of experiments aiming at evaluating the expres-
sion levels of cyclins expressed in the G1/S phase transition,
such as cyclin E and cyclin D1 (Adams, 2001). Western blot
analysis of total cell lysates for cell cycle proteins showed
that cyclin D1 and cyclin E were strongly induced after 16 h
of the addition of 10% FCS to the culture medium, compared
with the quiescent conditions containing 0.4% FCS (Fig. 5).
As expected, the addition of subliminal concentrations of
fluvastatin (2  106 M) that did not alter either [3H]thymi-
dine incorporation or cell cycle progression (Figs. 3 and 4) did
not significantly change both cyclin D1 and E expression
TABLE 1
Inhibitory effect of everolimus alone or in association with fluvastatin on cell proliferation
Assay
Inhibition (Conc.)
for
Fluvastatin
IC50
Ratio
Maximal Effect
(Conc.)
Everolimus
Everolimus

Fluvastatin
Everolimus
Everolimus

Fluvastatin
nM
Cell proliferation 9.2  8.4% (0.5 M) 2.5 1.0 2.5 54.9  12.9% (0.5 M) 72.4  8.3% (0.5 M)
Thymidine incorporation 14.2  9.1% (2 M) 6.5 0.19 34.2 63.3  4.6% (0.1 M) 75.9  2.4% (0.1 M)
Cell cycle (S phase) 3.2  23.8% (2 M) 76.9  3.8% (0.1 M) 83.4  1.5% (0.1 M)
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levels. However, 107 M everolimus reduced by 36.2 and
26.8% cyclin D1 and cyclin E levels, respectively (Fig. 5). The
addition of fluvastatin further enhanced the effect elicited by
everolimus, leading to 46.1 and 58.0% reduction of cyclin D1
and E, respectively. We next analyzed the expression levels
of cdk2 and its inhibitors p27Kip1 and p21Cip1. Whereas
p27Kip1 was not altered by either fluvastatin or everolimus
alone, the combination of everolimus with fluvastatin led a
significant increase of its expression levels by 47.0% com-
pared with everolimus alone (Fig. 5). In contrast, the addition
of fluvastatin to everolimus did not alter the expression lev-
els of both cdk2 and p21Cip1 in cells incubated with everoli-
mus alone. Nevertheless, everolimus alone significantly re-
duced the expression levels of p21Cip1 induced by the addition
of 10% FCS by 42% (Fig. 5).
Finally, we analyzed the phosphorylation state of Rb pro-
tein by Western blot analysis. The addition of 10% FCS to the
culture medium clearly induced Rb hyperphosphorylation,
an event that was not affected by fluvastatin but signifi-
cantly reduced by everolimus alone (43.2%) (Fig. 5). The
combination of everolimus and fluvastatin led to an almost
complete inhibition of Rb hyperphosphorylation (87.6%), a
condition similar to that observed in quiescent cells (0.4%
FCS), indicating a cell cycle arrest in G1.
Altogether, the present results indicate that everolimus
affected SMC proliferation by interfering with the progres-
sion of the G1 phase, reducing the expression of both cyclin
D1 and cyclin E and the phosphorylation of Rb protein. The
combination with subliminal concentrations of fluvastatin
resulted in a more significant inhibitory effect on SMC
growth and the expression of cyclin E and Rb phosphoryla-
tion, with increased p27Kip1 levels.
Overexpression of Cyclin E Confers a Partial Resis-
tance to the Antiproliferative Action of Combination
Everolimus Fluvastatin. To directly address the role of
cdk2/cyclin E complex on the synergistic effect of the combi-
nation everolimus fluvastatin, cyclin E were overexpressed
in rat SMCs. Western blot analysis of total cell lysates shows
that exogenous cyclin E was efficiently overexpressed in rat
SMCs compared with cells transduced with PURO control
vector (data not shown). These established cell lines were
then used for determining the antiproliferative action of the
combination fluvastatin everolimus. After 3 days, the combi-
nation of the two drugs (fluvastatin 5  107 M and everoli-
mus 107 M) led to 87.9 2.0% inhibition of cell proliferation
in control SMCs and 67.7  3.7% in cells overexpressing
cyclin E (Fig. 6A). A partial resistance was also observed by
evaluating the S phase entry determined by [3H]thymidine
incorporation assay and flow cytometry analysis after 16 h of
incubation with fluvastatin at 2  106 M and everolimus at
107 M (Fig. 6, B–D). Indeed, [3H]thymidine incorporation in
control and cyclin E-overexpressing cells was equal to 16.3 
0.4 and 24.9  4.8% versus control, respectively (Fig. 6B).
Quantification of the percentage of cells in S phase by cell
cycle analysis showed that, after 16 h of exposure to the drug
combination, a significant lower number of control cells was
replicating the DNA (8.64  0.6%) compared with cyclin
E-overexpressing cells (11.1  1.1%). The resistance of cells
overexpressing cyclin E was also confirmed by the presence of
higher hyperphosphorylated form of Rb after 16 h of expo-
sure to the drug combination compared with control cells
(Fig. 6D).
Taken together, the forced overexpression of cyclin E had a
slight, but significant impact on the antiproliferative action
of the combination everolimus fluvastatin, indicating that
Fig. 2. Effect of everolimus alone or in combination with fluvastatin on
HMG-CoA reductase activity, and p70S6 kinase and 4E-BP1 phosphory-
lation. A, synchronized rat SMCs were incubated for 72 h with DMEM
containing 10% FCS in the presence or absence of fluvastatin (5  107
M), everolimus (108 M), and their combination. After this period, the
HMG-CoA reductase activity was determined by measuring the rate of
conversion of radioactive HMG-CoA into mevalonate in detergent-solubi-
lized cell-free extract as described under Materials and Methods. Each
bar represents the mean  S.D. of triplicate samples. B, under the same
experimental conditions described for A, p70S6 kinase (p70S6K) expres-
sion and phosphorylation on threonine 412 (P-p70S6K) was determined
by Western blot analysis of total protein extracts using the polyclonal
antibodies anti-p70S6 kinase and anti-phospho-p70S6 kinase. The same
analysis was performed to evaluate the expression levels and the phos-
phorylation state for 4E-BP1. C, under the same experimental conditions,
cell number was evaluated by cell counting after incubation with fluva-
statin (5 107 M), everolimus (108 and 109 M), and their combination
in the presence or absence of MVA (104 M), FOH (105 M), or GGOH
(5  106). Each bar represents the mean  S.D. of two different exper-
iments. Statistical analysis was performed by Student’s t test. NS, not
significant.
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cyclin E down-regulation is required for a full exploitation of
the inhibition of cell growth by these two drugs.
Discussion
The Combination of Subliminal Concentrations of
Fluvastatin Synergistically Improve the Antiprolifera-
tive Action of Everolimus. The present study was under-
taken to explore the antiproliferative action of everolimus on
rat aortic SMC proliferation alone and in combination with
fluvastatin. The present findings demonstrated, for the first
time, a synergistic antiproliferative effect between fluva-
statin and everolimus measured by cell counting after 3 days
of exposure to the drugs and by [3H]thymidine incorporation
assay after 16 h of incubation (Table 1). Moreover, by biolog-
ical and pharmacological approaches and genetic modifica-
tion of rat SMCs, we demonstrated that the synergistic effect
of this drug combination converges on the regulation of cy-
clinE/p27kip1 complex, leading to a block in G1 phase of the
cell cycle.
The IC50 values, a measure of pharmacological potency,
showed that everolimus plus fluvastatin was, respectively,
2.5- and 32.7-fold more potent than everolimus alone to affect
cell proliferation and [3H]thymidine incorporation, respec-
tively (Table 1). In terms of efficacy, everolimus led to a
growth inhibition up to 54.9  12.9%, an effect that was
enhanced to 72.4  8.3% by the combination with subliminal
concentration of fluvastatin (Table 1). Similar plateau of
about 55% inhibition was also observed in previous studies
conducted with everolimus in tumor cell lines, and associa-
tion with other chemotherapeutic agents led to a more pro-
found inhibitory activity (Haritunians et al., 2007). The anal-
ysis of drug interaction clearly demonstrated that the
antiproliferative effect of everolimus in the presence of a
subliminal concentration of fluvastatin was synergistic at
concentration of everolimus higher than 5  109 M
The Synergistic Antiproliferative Effect of Everoli-
mus Fluvastatin Is Elicited in G1 Phase of the Cell
Cycle by Affecting p27kip1/Cyclin E Expression. Be-
cause flow cytometry analysis of the cell cycle supports the
possibility that fluvastatin enhances the inhibitory effect of
everolimus at the level of the progression of G1/S phase, we
studied the expression levels of G1 phase proteins byWestern
blot analysis.
The current knowledge of the molecular mechanism for cell
cycle entry of eukaryotic cells emphasized a pivotal role for
cdk4/cdk6 and cdk2 and their respective cyclin partners cy-
clins D1, D2, D3, E, and A (Adams, 2001). In particular, the
expression of D type cyclins seems to be controlled by the
extracellular mitogens, and, once induced, D type cyclins
associate with cdk4 and cdk6, mediating the phosphorylation
of Rb protein. In contrast, the expression of E type cyclins is
controlled by an autonomous mechanism and peaks sharply
at the G1/S border (Ekholm and Reed, 2000; Aleem et al.,
2005), and they are believed to complete the phosphorylation
of pRb, initiated by the action of cyclin D-cdk complexes
(Stacey, 2003; Fu et al., 2004). More recently, the generation
of cyclin E knockout mice allowed for the demonstration of
their essential function in cell cycle re-entry (Geng et al.,
2003). In our study, the antiproliferative effect of the tested
drugs was assessed in SMCs previously synchronized in G0
phase of the cell cycle and then stimulated by the addition of
10% FCS. Under these experimental conditions, the up-reg-
ulation of cyclin E is absolutely required for cell cycle pro-
gression (Geng et al., 2003). Consistently with previous stud-
ies conducted with rapamycin in SMCs (Braun-Dullaeus et
al., 2001), everolimus did not affect p27kip1 expression levels
in SMCs, but a significant up-regulation (47.0%) was ob-
Fig. 3. Effect of everolimus alone or in combination
with fluvastatin on [3H]thymidine incorporation.
Cells were seeded at a density of 2  105 per 35-mm
dish and incubated with DMEM supplemented with
10% FCS. Twenty-four hours later, the medium was
changed with medium containing 0.4% FCS to stop
cell growth, and the cultures were incubated for 5
days. At this time, the medium was replaced with
medium containing 10% FCS, in the presence or
absence of indicated concentrations of drugs. After
16 h, at 37°C, cells were labeled with [3H]thymidine
for 2 h, and radioactivity was evaluated. Each bar
represents the mean  S.D. of triplicate dishes. ,
p  0.05 and , p  0.001, treatment versus con-
trol (Student’s t test). The data are representative of
three replicate experiments. Synergistic interaction
between everolimus and fluvastatin is evidenced by
the R value greater than unity (Kern et al., 1988).
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served only in combination with fluvastatin. In contrast,
everolimus alone, similar to rapamycin (Braun-Dullaeus et
al., 2001), significantly affected cyclin E (26.8%) and cyclin
D1 expression (36.2%), and the combination with fluva-
statin enhanced the effect of everolimus on cyclin E (from
26.8 to 58.0%), but only slightly affect the expression of
cyclin D1 (from 36.2 to 46.1%). As shown previously by
others, up-regulation of the cyclin-dependent kinase inhibi-
tor p21Cip1 in response to 10% FCS was prevented by everoli-
mus, although the addition of fluvastatin did not further
increased this effect (Braun-Dullaeus et al., 2001). A signif-
icant change was also observed after the addition of fluva-
statin to the action of everolimus on the levels of Rb hyper-
phosphorylation, which changed from 43.2 to 87.6%.
It was therefore conceivable to hypothesize that the reduc-
tion of cyclin E expression by combination of the two drugs
may be responsible for the inhibition of the progression of the
G1 phase. The forced overexpression of cyclin E in rat SMC by
retroviral infection conferred a partial but significant resis-
tance to the antiproliferative action of the combination
everolimus fluvastatin. This effect was observed on four dif-
ferent parameters related to cell proliferation: cell number
after 3 days of exposure, [3H]thymidine incorporation, cell
cycle analysis of S phase, and Rb phosphorylation. These
results suggest that the synergistic antiproliferative effect of
the combination everolimus fluvastatin is partially mediated
by the inhibition of the kinase activity of cdk2/cyclin E.
Everolimus and Fluvastatin Act on the Same Phase
of the Cell Cycle by Inhibiting Different Intracellular
Targets. Several studies have demonstrated that statins
cause G1 arrest by increasing cellular p27
kip1 levels and
reducing cyclin E expression (Laufs et al., 1999; Rao et al.,
1999; Fouty and Rodman, 2003). This effect has been as-
cribed to different prenylated proteins, including Ras and
Fig. 4. Effect of everolimus alone or in combination with fluvastatin on cell cycle of rat SMC. Experimental conditions are as in Fig. 3. Representative
flow cytometry analysis of rat SMCs incubated with indicated concentrations of drugs are shown. Tables summarizing flow cytometry analysis of cell
cycle performed in the presence of 0.4 and 10% FCS alone, or 10% FCS with reported concentrations of drugs are shown below each panel. The analysis
was performed by using the ModFit LT software (Verity Software House). The data are representative of two replicate experiments. , p  0.05,
everolimus versus everolimus  fluvastatin (Student’s t test).
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Rho GTP-binding proteins. Considerable evidence also indi-
cates that mTORC1 inhibitors, such as rapamycin, similarly
to statins, affect SMC proliferation by blocking in G1 phase
through a reduction of the expression of several cell cycle
proteins, including cyclin D1 and cyclin E (Braun-Dullaeus et
al., 2001), whereas its effect on p27kip1 expression levels is
still controversial (Gallo et al., 1999; Braun-Dullaeus et al.,
2001).
In our study, we have shown that the combination of the
two drugs significantly affects the expression of cyclin E and
p27kip1. The subliminal concentrations of fluvastatin used
significantly affected the HMG-CoA reductase activity (Fig.
2) without altering cell proliferation and cell cycle molecule
expression (Fig. 5). It is therefore tempting to speculate that
fluvastatin, by reducing the intracellular synthesis of MVA
and its isoprenoid derivatives, may alter turnover and func-
tion of Ras and/or Rho GTP-binding proteins, facilitating the
antiproliferative effect of everolimus. This hypothesis is sup-
ported by the evidence that the coincubation with MVA, FOH
or GGOH significantly prevented the additive effect of fluva-
statin on the antiproliferative action of everolimus (Fig. 2C).
Evidence indicates that at least two farnesylated proteins
and one geranylgeranylated protein are involved in the sig-
naling of growth factors to mTORC1 complex: Ras, Rheb, and
Cdc42 (Fang et al., 2003; Long et al., 2005; Ma et al., 2005).
Ras/extracellular signal-regulated kinase pathway is respon-
sible for the phosphorylation of tuberin event that negatively
regulates tuberin function by blocking the interaction with
hamartin, leading to the activation of farnesylated Rheb and
mTORC1 complex (Shaw and Cantley, 2006). Alteration of
the intracellular isoprenoid metabolism may therefore alter
both Ras and Rheb, two positive regulators of mTORC1 com-
plex. In agreement with this hypothesis, the specific farnesyl
transferase inhibitor SCH66336 has been shown to effi-
ciently inhibit Rheb prenylation and mTOR signaling asso-
ciated with reduced levels of phosphorylated S6 (Basso et al.,
2005). A second mode of mTORC1 regulation has been re-
ported to occur via phosphatidic acid generated by phospho-
lipase D. The activity of phospholipase D is known to be
Fig. 5. Effect of everolimus alone or in combination with fluvastatin on
cell cycle proteins. Experimental conditions are as in Fig. 2. Cell cycle
protein expression levels were evaluated by Western blot analysis. The
concentration of fluvastatin and everolimus was 2  106 and 107 M,
respectively. Quantitative densitometric analysis was performed with
GelDoc acquisition system and Quantity One software. The data are
expressed as relative values, and they are representative of three repli-
cate experiments.
Fig. 6. Effect of cyclin E overexpression on the antiproliferative action of
combination everolimus fluvastatin. A, antiproliferative action of combi-
nation everolimus (107 M) fluvastatin (5 107 M) was evaluated in rat
SMCs transduced with pBM-IRES-PURO retrovirus encoding control
vector (PURO) and cyclin E (CycE). B, the same cells described in A were
used for determining the [3H]thymidine incorporation after 16 h of incu-
bation with combination everolimus (107 M) fluvastatin (2  106 M).
The same experimental conditions described for B were used for cell cycle
analysis (C) and the determination of Rb phosphorylation state by West-
ern blot analysis (D). Each bar represents the mean  S.D. of triplicates.
The data are representative of two replicate experiments.
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dependent on the small GTPase protein Cdc42 (Fang et al.,
2003) and therefore potentially affected by the action of flu-
vastatin. It is noteworthy that the two modes of regulation of
mTORC1 seem to interplay (Fang et al., 2003).
A second plausible explanation for the synergistic effect
might be related to the interference of everolimus and fluva-
statin on two distinct intracellular signaling pathways regu-
lating the G1 phase transition, mTORC1/p70S6 kinase and
Rho/p27kip1, respectively (Laufs et al., 1999). This possibility
seems to be the most likely because everolimus by completely
blocking the p70S6 kinase phosphorylation, a downstream
effector of Ras, Rheb, and Cdc42, should not allow a further
inhibition of this pathway by fluvastatin (Fig. 5).
Taken together, although the basic molecular mechanism
that governs the synergistic effect of everolimus and fluva-
statin is far from being understood, several indications point
out a potential role of prenylated proteins. Future studies
will be undertaken to identify which prenylated protein(s) is
indeed involved in this process.
In conclusion, we provide evidence that everolimus and flu-
vastatin act synergistically to inhibit rat SMC proliferation in
vitro, by altering the expression of cyclin E and p27kip1, which
affect Rb hyperphosphorylation leading to G1 phase arrest.
These results represent the basis for further experimental stud-
ies addressing the relevance of the synergistic properties of the
combination everolimus and fluvastatin.
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Correction to “Fluvastatin Synergistically Improves
the Antiproliferative Effect of Everolimus on Rat
Smooth Muscle Cells by Altering p27Kip1/Cyclin E
Expression”
In the above article [Ferri N, Granata A, Pirola C, Torti F, Pfister PJ, Dorent R, and
Corsini A (2008) Mol Pharmacol 74:144-153], the IC50 units and values in Table 1 were
incorrect because of an error during copyediting. The corrected table appears in its
entirety below:
The online version has been corrected in departure from the print version.
The printer regrets this error and apologizes for any confusion or inconvenience it may
have caused.
Correction to “Slc39a14 Gene Encodes ZIP14,
A Metal/Bicarbonate Symporter: Similarities
to the ZIP8 Transporter”
In the above article [Girijashanker K, He L, Soleimani M, Reed JM, Li H, Liu Z, Wang
B, Dalton TP, and Nebert DW (2008)Mol Pharmacol 73:1413-1423], some exponents were
incorrectly reported as positive rather than negative. UnderMaterials andMethods, in the
Quantitative Polymerase Chain Reaction Analysis section, the first sentence of the second
paragraph should read “The range of calibration curves was linear from 103 to 107 g
of plasmid (r  0.999 for ZIP14A, 0.998 for ZIPB, and 0.995 for ZIP8).”
The authors regret this error and apologize for any confusion or inconvenience it may
have caused.
TABLE 1
Inhibitory effect of everolimus alone or in association with fluvastatin on cell proliferation
Assay
Inhibition (Conc.)
for
Fluvastatin
IC50
Ratio
Maximal Effect
(Conc.)
Everolimus
Everolimus

Fluvastatin
Everolimus
Everolimus

Fluvastatin
nM
Cell proliferation 9.2  8.4% (0.5 M) 2.5 1.0 2.5 54.9  12.9% (0.5 M) 72.4  8.3% (0.5 M)
Thymidine incorporation 14.2  9.1% (2 M) 6.5 0.19 34.2 63.3  4.6% (0.1 M) 75.9  2.4% (0.1 M)
Cell cycle (S phase) 3.2  23.8% (2 M) 76.9  3.8% (0.1 M) 83.4  1.5% (0.1 M)
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